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“[A reply to letters recommending remedies]: Dear Sir (or Madam): I try every remedy sent to me. I am
now on No. 67. Yours is 2,653. I am looking forward to its beneficial results.”
Mark Twain, quoted inMy Father Mark Twain, by Clara Clemens
THE TREATMENT REVOLUTION IN RHEUMATOLOGY
The field of rheumatology has witnessed astonishing progress in the understanding and
management of rheumatic diseases since the second half of the twentieth century. The discovery
and introduction of glucocorticoids and conventional synthetic disease-modifying antirheumatic
drugs (csDMARDs) into the therapeutic armamentarium of rheumatologists enabled, for the first
time, to effectively change the natural course of disease and improve most clinical outcomes
(1). The new millennium pushed the revolution further at an exponential level with the advent
of sophisticated, biologically-engineered drugs—the so-called biologicals or bDMARDs—that
targeted specific molecules in key pathogenic pathways and dramatically modified the prognosis
of most patients with immune-mediated rheumatic diseases (2).
This progress, which was driven by tremendous research efforts to better understand the
complex mechanisms behind each disease, has been particularly remarkable in inflammatory
joint diseases such as rheumatoid arthritis (RA) and spondyloarthritis (including ankylosing
spondylitis and psoriatic arthritis), and slower in the area of connective tissue diseases (e.g.,
systemic lupus erythematosus, Sjögren’s syndrome) and vasculitis. Indeed, as of March 2019,
10 original bDMARDs with 5 different mechanisms of action are approved in Europe for the
treatment of RA, 9 for psoriatic arthritis (4 mechanisms of action), 6 for ankylosing spondylitis
(2 mechanisms of action), only 1 for systemic lupus erythematosus and small-vessel vasculitis and
none for Sjögren’s syndrome (3).
Yet, despite these significant advances, major unmet needs endure. The case of RA is
paradigmatic of the current challenges faced by rheumatologists and patients alike in daily clinical
practice. While at first, and especially when paralleled to other rheumatic diseases, RA seems to
be the lucky relative of the rheumatology family with a variety of innovative bDMARDs available
for treating and modifying the disease and improving patients’ lives and outcomes, in practice the
reality is more complex (4, 5).
“ME-TOO” DRUGS AND THE TRIAL AND ERROR APPROACH
Firstly, after the major breakthroughs shown around the turn of the millennium by the pioneer
bDMARDs approved for RA (infliximab and etanercept) in comparison to the standard of care
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available at the time (csDMARDs), the following decade observed
a surge of other drugs that demonstrated a comparable effect
in similar populations of patients (6). With a few exceptions
(e.g., tocilizumab and sarilumab exhibiting superiority over
methotrexate in monotherapy), new coming therapies usually
conveyed a “me-too” effect that though important to increase
treatment options in the event of inefficacy or intolerance, did
not generate as tremendous an impact as its predecessors (7).
Secondly, the wide diversity of bDMARDs and modes of
action contrasts with the profound lack of reliable, reproducible
clinical and biological markers to inform treatment selection.
Indeed, in spite of all the notable progress seen so far, we are
somewhat surprisingly unable to recognize beforehand which
individual patients will benefit more from a given drug, which
will not respond at all and which are at a higher risk of
toxicity or intolerance (8). Taking the specific example of RA,
it should be acknowledged that there are a few well-established
prognostic indicators that are associated at a group level with
treatment-resistant disease, including female gender, older age,
long lasting disease, failure of previous biologics, smoking, and
high baseline disability (8, 9). But these features seem to be
generically associated with worse treatment outcomes as a whole,
rather than constituting specific predictors of response to a given
drug. A couple of exceptions exist, such as the role of rheumatoid
factor / anti-citrullinated protein antibodies seropositivity in
determining a better response to rituximab (10) and abatacept
(11) but also here this is a group effect and some seronegative
patients will still show improvement with these treatments,
while other seropositive patients will not experience any benefit.
Other variables such as relevant comorbidities (e.g., lymphoma
or monoclonal gammopathy) or infectious risk may further
concede slight preference of one bDMARDover another and thus
aid in the treatment decision process (12, 13), although again
this is not driven by a particularly strong factor that identifies
the best treatment for a given patient. This current landscape
has inevitably led to the so-called trial and error approach
that is the hallmark of present treatment strategies in RA and
other inflammatory joint diseases and which has significant
implications in terms of cost, risk and, ultimately, outcome.
LIMITATIONS OF PRESENT TREATMENT
MODALITIES
Undeniably, coupled with the major benefits brought by these
therapies, a few shortcomings have emerged. These are powered
by the aforementioned unprecise treatment paradigm, with
implications both at the patient and societal level. The first factor
is related to the significant direct costs associated with these
drugs, which has put additional financial pressure in already
struggling healthcare systems (14). However, it has been shown
that the overall cost associated with RA management has not
increased significantly over the last decades, due to a major
drop in indirect costs and productivity losses that compensated
for the higher drug-related expenditure (14, 15). In fact, the
main concern is that lacking robust personalized treatment
strategies, patients may be treated with costly bDMARDs for
an extended period of time without experiencing any relevant
benefit but still be exposed to its risks and potential adverse
events. It is remarkable that in such a case, the risk-benefit ratio
is clearly tilted in the wrong direction, and yet, health authorities,
physicians and patients, all seem to ignore or accept this fact
as inevitable.
Currently, bDMARDs have a well-established safety profile
(16), that needs to be balanced against the corresponding
benefits provided by the treatment itself. A number of serious
conditions—such as tuberculosis and other serious infections
or liver and medullary toxicity, to name just a few (17)—are
associated with bDMARDs and are accepted only in return for
substantial efficacy and improvement of short- and long-term
outcomes. If this second part of the equation is missing, as
is the case of the considerable proportion of patients that fail
to see any benefit at all, it may be ethically (and financially,
as explained above) unacceptable to prescribe and administer
these drugs. Hence, the problem relies in the fact that we
are unable to identify these patients beforehand, emphasizing
the limitations of this treatment model and the need for an
individualized approach. The scenario is aggravated whenwe also
take into account the short-term, highly-intensive, remission-
inducing regimens that are applied in several rheumatic diseases,
usually with substantial toxicity, in an indiscriminate manner
(18–20). These treatment modalities represent the standard of
care, but personalized treatment could revolutionize the current
paradigm of an all-or-nothing approach simply based on the
existence of a certain diagnosis.
Another aspect that should be considered when analyzing
the issue of undiscerning drug selection is effective treatment
delay. Treat-to-target (T2T) approaches have shown that, in
terms of prognosis, more important than the drug administered
is the therapeutic target defined and the quickness to attain
it (21, 22). Subjecting patients to treatments that will not be
effective for long periods—at least 3 to 6 months as per standard
recommendations (23)—will cost precious time during which
disease activity is high and structural damage readily occurs.
This leads to poor long-term outcomes and is yet another reason
for why a generalized same-drug-for-all strategy is flawed. The
discovery of precise biomarkers of response to inform treatment
selection could save up this lost time and, thus, synergistically
reinforce the T2T strategy. In spite of this, T2T advocates
have, somewhat surprisingly, disregarded the importance of
personalized medicine vs. the main goal of abating disease
activity regardless of the mechanism implied and drug chosen
(24). However, as they point out, this only reflects the current
standing, where precise biomarkers that have a major impact on
treatment selection and canmodify and guide clinical practice are
still missing (8, 25).
Importantly, one should not forget other additional
factors contributing to treatment limitations. Despite major
improvements in the area of early diagnosis, it has recently been
reported that in daily clinical practice the reality is still far from
optimal (26–28). Moreover, there has also been a continuous
global effort for the development and update of classification
criteria of rheumatic diseases, but these are aimed at patient
recruitment in research studies, in most cases perform poorly
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in a real-world setting, and therefore should not be applied
for clinical diagnosis (29). Finally, with the incorporation into
routine care of highly sensitive diagnostic techniques such as
ultrasonography or magnetic resonance imaging, the concern
of overdiagnosis and overtreatment of rheumatic diseases is
already a reality, that should be addressed (30). These aspects
allow to better understand the delicate landscape in which
drugs are prescribed and underscore the need to improve
treatment approaches.
NEW PLAYERS: THE ROLE OF
BIOSIMILARS AND NOVEL TARGETED
SYNTHETIC MOLECULES
As we have exposed, currently available bDMARDs compose
an heterogeneous group of drugs, with several modes of
action, distinct dosages, schedules, and routes of administration
and some particularities in terms of concomitant medication,
monitoring, or adverse events. However, the overall efficacy and
safety between bDMARDs is considered to be roughly similar
and long-term outcomes of patients treated with these drugs
are not substantially different (2, 7). For this matter, we should
highlight the importance of disease registers, both national and
international, which have greatly contributed to demonstrate the
benefits and pitfalls of treatments in a real-life setting (31).
It is in this setting that in the last 5–10 years two new treatment
classes have appeared to add to the complexity of rheumatic
patients management: biosimilar DMARDs (bsDMARDs or
biosimilars) and targeted synthetic DMARDs (tsDMARDs). Both
have contributed to widen the options available for treating RA
patients, but also brought along additional challenges to the table.
Biosimilars emerged following the patent expiry of bDMARDs
and promised to increase patient access by significantly
decreasing treatment costs while, simultaneously, showing
comparable efficacy and safety (32, 33). Following rigorous
clinical trial programs demonstrating equivalence to the original
bDMARDs, there are currently 16 bsDMARDs approved in
Europe for the treatment of RA (4 infliximab, 3 etanercept,
6 adalimumab, 3 rituximab), with others awaiting approval (2
adalimumab), already withdrawn (2 adalimumab) or not having
applied for RA indication (3 rituximab) (3). These impressive
numbers speak well to the potential impact of bsDMARDs in the
field. Indeed, its main added value relies in the reduced cost-−20
to 40% below reference bDMARDs, depending on country—and,
consequently, the larger number of patients that can be treated
with these drugs (33, 34). While this partially resolves one of the
issues mentioned above (cost), the other two (safety and time
lost) remain unchanged. Ultimately, the increase in offer could
even amplify the problem, with patients switching often between
different bDMARDs and bsDMARDs in the pursuit of the right
drug, with the associated implications in treatment delay and
pharmacovigilance issues. This further reinforces the need for
patient stratification and rational treatment selection.
Nonetheless, bsDMARDs have undoubtedly opened a new era
in the treatment of rheumatic diseases. Rates of first bsDMARD
are rising in Europe (34), and after the main pivotal trials,
good quality observational data have confirmed the safety of
switching patients from the original drug to its biosimilar (35–
37). Concurrently, other challenges arise, such as selection and
switching between biosimilars of the same bDMARD, different
immunogenicity patterns and, potentially, lack of evidence for
established prognosis markers that may differ from those known
for the original drug (35, 36). This latter aspect may be fueled by
a low willingness of bsDMARD drug developers to better explore
disease heterogeneity, as this could potentially be commercially
unattractive and limit the promotion of these drugs. Additionally,
the nocebo effect—the negative effect of a treatment that is
attributable to poor patient expectations—is a well-defined
phenomenon that is particularly troublesome when switching
real-world patients from original bDMARDs to bsDMARDs,
due to the importance played by subjective measures (e.g., pain
and global assessment, tender joint counts) in the evaluation of
disease activity and treatment response (38).
A novel class of oral highly specific small molecules inhibiting
intracellular signaling pathways, the tsDMARDs, has also become
available (39). Tofacitinib, a Janus kinase inhibitor approved
in the United States (2012) and Europe (2017), was recently
followed by baricitinib (2018 and 2017, respectively) as the first
two oral drugs that have an efficacy and safety profile comparable
to bDMARDs (40). This is a major advance, given the preference
of many patients for oral vs. parenteral administration. Other
potential advantages include rapid clinical efficacy, even in
monotherapy, absence of immunogenicity and a shorter half-
life, facilitating the management of adverse drug reactions (39,
40). However, its place in treatment algorithms (before or
after cs/b/bsDMARDs) is still to be fully understood. Most
importantly, while tsDMARDs will definitely be beneficial for
a large number of patients, the lack of predictive biomarkers
precludes its rational application at the individual patient level
and its introduction in the clinical armamentarium follows the
same trial and error approach.
THE LAG OF PERSONALIZED MEDICINE
IN RHEUMATOLOGY
A number of reasons can be put forward as to why personalized
medicine is taking a long time to materialize in rheumatology.
First, the heterogeneous and multifactorial nature of immune-
mediated rheumatic diseases, with complex pathogeneses,
makes it unlikely that a single marker of a given pathway
will discriminate response of several different DMARDs with
contrasting modes of action (41). Second, a considerable amount
of effort is dedicated to identifying biomarkers in the blood, far
from the key immunopathologic events happening at the synovial
tissue, which may prove more informative (42). Third, one aspect
that is not so commonly cited relates to the subjective nature of
a significant part of the tools used to assess treatment response,
remission status or disability. This applies both to the patient
(e.g., visual analog scale) and the physician (e.g., joint counts)
and is, by definition, influenced by many other individual-related
factors, such as personality, previous experience with a given
drug, expectations, patient-doctor relationship, cultural context,
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comorbidities, etc. (43, 44). Indeed, this scarcity of hard outcomes
contrasts to that seen, for instance, in the area of oncology
(e.g., death, tumor-free survival), where personalized treatment
has long been a reality. To what extent is the current situation
explained by this fact is unclear, but subjective measures are
likely to play an important role in confounding study results,
potentially leading to the loss of a weak, albeit unique signal.
CONCLUSIONS AND FUTURE
PERSPECTIVES
In summary, the present moment in rheumatology is an exciting
one, after two fast-paced decades that transformed the prognosis
of patients with inflammatory rheumatic diseases. This was
mainly due to a deep expansion of available, effective therapies
that have come, nonetheless, coupled with major challenges
that need to be tackled. We argue that this is the time
to do so, where research efforts should be best directed at
establishing robust biomarker-based treatment models that will
allow individualized care. If successful, the outcome of this
approach is likely to translate into more substantial benefits,
compared to the meek pursuit of new drugs—often with the
same or close mechanisms of action—that will provide a similar
overall effect to currently available options. Synovial tissue
should be at the center of these investigations, as targeting the
disease process at its core will arguably prove most valuable.
This is definitely a sinuous path, not without many expectable
setbacks, but one worth tracking as its completion may finally
lead to a new longed-for era of personalized medicine in
rheumatology. Notably, despite all the cutting-edge science
behind these innovations, clinical expertise of rheumatologists
will be of strategic importance in guiding the process along
the way.
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